Literature DB >> 22535639

Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells.

Marielle A Otten1, Jantine E Bakema, Cornelis W Tuk, Martin J Glennie, Alison L Tutt, Robert H J Beelen, Jan G J van de Winkel, Marjolein van Egmond.   

Abstract

Neutrophils potently kill tumour cells in the presence of anti-tumour antibodies in vitro. However, for in vivo targeting, the neutrophils need to extravasate from the circulation by passing through endothelial barriers. To study neutrophil migration in the presence of endothelial cells in vitro, we established a three-dimensional collagen culture in which SK-BR-3 tumour colonies were grown in the presence or absence of an endothelial barrier. We demonstrated that - in contrast to targeting FcγR on neutrophils with mAbs - targeting the immunoglobulin A Fc receptor (FcαRI) instead triggered neutrophil migration and degranulation leading to tumour destruction, which coincided with release of the pro-inflammatory cytokines interleukin (IL)-1β and tumour necrosis factor (TNF)-α. Interestingly, neutrophil migration was enhanced in the presence of endothelial cells, which coincided with production of significant levels of the neutrophil chemokine IL-8. This supports the idea that stimulation of neutrophil FcαRI, but not FcγR, initiates cross-talk between neutrophils and endothelial cells, leading to enhanced neutrophil migration towards tumour colonies and subsequent tumour killing.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22535639     DOI: 10.1002/eji.201141982

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.

Authors:  Niels Heemskerk; Mandy Gruijs; A Robin Temming; Marieke H Heineke; Dennis Y Gout; Tessa Hellingman; Cornelis W Tuk; Paula J Winter; Suzanne Lissenberg-Thunnissen; Arthur Eh Bentlage; Marco de Donatis; Marijn Bögels; Thies Rösner; Thomas Valerius; Jantine E Bakema; Gestur Vidarsson; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

Review 2.  Protumor and antitumor functions of neutrophil granulocytes.

Authors:  Sven Brandau; Claudia A Dumitru; Stephan Lang
Journal:  Semin Immunopathol       Date:  2012-09-25       Impact factor: 9.623

Review 3.  Neutrophil diversity and plasticity in tumour progression and therapy.

Authors:  Sebastien Jaillon; Andrea Ponzetta; Diletta Di Mitri; Angela Santoni; Raffaella Bonecchi; Alberto Mantovani
Journal:  Nat Rev Cancer       Date:  2020-07-21       Impact factor: 60.716

4.  A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.

Authors:  Gerard Ja Rouwendal; Miranda M van der Lee; Saskia Meyer; Karli R Reiding; Jan Schouten; Guy de Roo; David F Egging; Jeanette Hw Leusen; Peter Boross; Manfred Wuhrer; Gijs F Verheijden; Wim H Dokter; Marco Timmers; Ruud Ubink
Journal:  MAbs       Date:  2015-10-06       Impact factor: 5.857

5.  IL-1 Contributes to the Anti-Cancer Efficacy of Ingenol Mebutate.

Authors:  Thuy T Le; Kresten Skak; Kate Schroder; Wayne A Schroder; Glen M Boyle; Carly J Pierce; Andreas Suhrbier
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 6.  Monoclonal antibody-mediated killing of tumour cells by neutrophils.

Authors:  Niels Heemskerk; Marjolein van Egmond
Journal:  Eur J Clin Invest       Date:  2018-07-05       Impact factor: 4.686

Review 7.  IgA and FcαRI: Pathological Roles and Therapeutic Opportunities.

Authors:  Annelot Breedveld; Marjolein van Egmond
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 8.  Avidity in antibody effector functions and biotherapeutic drug design.

Authors:  Simone C Oostindie; Greg A Lazar; Janine Schuurman; Paul W H I Parren
Journal:  Nat Rev Drug Discov       Date:  2022-07-05       Impact factor: 112.288

Review 9.  Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils.

Authors:  Leonie M Behrens; Timo K van den Berg; Marjolein van Egmond
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.